能特科技：2025年全年净利润同比预增134.01%—142.51%

Core Viewpoint - The company Nengte Technology has released its annual performance forecast, expecting a significant increase in net profit for 2025, driven primarily by the growth in its vitamin E business, despite challenges in its pharmaceutical intermediates segment and other non-recurring losses [1] Group 1: Financial Performance - The company anticipates a net profit attributable to shareholders of approximately 200 million to 250 million yuan for 2025, representing a year-on-year increase of 134.01% to 142.51% [1] - The expected net profit after deducting non-recurring gains and losses is projected to be around 320 million to 390 million yuan, reflecting a year-on-year increase of 162.06% to 175.63% [1] Group 2: Business Segments - The vitamin E business is expected to contribute no less than 660 million yuan to the company's profits, significantly boosting overall performance for 2025 [1] - The pharmaceutical intermediates segment, particularly the sales of Montelukast sodium intermediates, has underperformed due to delayed market demand and lower-than-expected sales [1] - The competition in the market for Rosuvastatin intermediates has intensified, leading to a decline in market prices and profits [1] Group 3: Non-Recurring Items - The company plans to recognize an impairment loss of no more than 260 million yuan related to goodwill due to the underperformance of the pharmaceutical intermediates [1] - The sale of a wholly-owned subsidiary, Shaanxi Ankang Shenqian Mining Co., Ltd., is expected to reduce profits by 48.87 million yuan, categorized as a non-recurring loss [1] - Legal proceedings are anticipated to result in a profit reduction of 79.59 million yuan for 2025, also classified as a non-recurring loss [1]